2024
Stress-induced mucin 13 reductions drive intestinal microbiome shifts and despair behaviors
Rivet-Noor C, Merchak A, Render C, Gay N, Beiter R, Brown R, Keeler A, Moreau G, Li S, Olgun D, Steigmeyer A, Ofer R, Phan T, Vemuri K, Chen L, Mahoney K, Shin J, Malaker S, Deppmann C, Verzi M, Gaultier A. Stress-induced mucin 13 reductions drive intestinal microbiome shifts and despair behaviors. Brain Behavior And Immunity 2024, 119: 665-680. PMID: 38579936, PMCID: PMC11187485, DOI: 10.1016/j.bbi.2024.03.028.Peer-Reviewed Original ResearchMicrobiome shiftsDespair behaviorTranscription factor familyChronic stressRegulation of mucinsState of dysbiosisMicrobiome composition changesAssociated with disease pathologyDepressive-like symptomsModel of chronic stressLimited treatment optionsContext of stressHuman microbiomeMicrobiome compositionPsychological stress exposureMicrobial compositionFactor familyMicrobial dysbiosisMicrobial changesMicrobiome dysbiosisMicrobiomeTreatment optionsUpstream mediatorDepressive symptomsStress exposure
2023
Ensuring Dermatologists Practice Enhanced Antibiotic Stewardship With Sarecycline Mnemonic.
Borash J, Bunick C, Graber E. Ensuring Dermatologists Practice Enhanced Antibiotic Stewardship With Sarecycline Mnemonic. Journal Of Drugs In Dermatology 2023, 22: 1061. PMID: 37801533, DOI: 10.36849/jdd.7138.Peer-Reviewed Original ResearchConceptsAntibiotic stewardshipMicrobiome dysbiosisJ DrugsDermatologists' practiceAntimicrobial resistanceThe effect of single dose albendazole (400 mg) treatment on the human gut microbiome of hookworm-infected Ghanaian individuals
Appiah-Twum F, Akorli J, Okyere L, Sagoe K, Osabutey D, Cappello M, Wilson M. The effect of single dose albendazole (400 mg) treatment on the human gut microbiome of hookworm-infected Ghanaian individuals. Scientific Reports 2023, 13: 11302. PMID: 37438457, PMCID: PMC10338455, DOI: 10.1038/s41598-023-38376-3.Peer-Reviewed Original ResearchConceptsHookworm infectionAlbendazole treatmentMicrobiota compositionStool samplesGut microbiomeGut microbiome dysbiosisInfection cure rateKintampo North MunicipalityPre-treatment statePotential microbial biomarkersAdjunct treatmentAnthelminthic therapySingle doseCure rateMicrobiome dysbiosisTreatment outcomesGut homeostasisPharmacological responseProbiotic supplementationGut microbiotaUninfected individualsCommensal bacteriaInfected individualsTherapy outcomeHuman gut microbiome
2022
Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia
Bernard-Raichon L, Venzon M, Klein J, Axelrad J, Zhang C, Sullivan A, Hussey G, Casanovas-Massana A, Noval M, Valero-Jimenez A, Gago J, Putzel G, Pironti A, Wilder E, Thorpe L, Littman D, Dittmann M, Stapleford K, Shopsin B, Torres V, Ko A, Iwasaki A, Cadwell K, Schluter J. Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia. Nature Communications 2022, 13: 5926. PMID: 36319618, PMCID: PMC9626559, DOI: 10.1038/s41467-022-33395-6.Peer-Reviewed Original ResearchConceptsGut microbiome dysbiosisCOVID-19 patientsMicrobiome dysbiosisSecondary infectionSARS-CoV-2 infection inducesLife-threatening secondary infectionsTranslocation of bacteriaBlood culture resultsCOVID-19 severityAntimicrobial-resistant speciesCOVID-19Different clinical sitesMicrobial translocationBloodstream infectionsInfection inducesBarrier permeabilitySystemic circulationDysbiosisGoblet cellsPaneth cellsClinical sitesCulture resultsPatient healthGut microbiomePatients
2020
Global chemical effects of the microbiome include new bile-acid conjugations
Quinn RA, Melnik AV, Vrbanac A, Fu T, Patras KA, Christy MP, Bodai Z, Belda-Ferre P, Tripathi A, Chung LK, Downes M, Welch RD, Quinn M, Humphrey G, Panitchpakdi M, Weldon KC, Aksenov A, da Silva R, Avila-Pacheco J, Clish C, Bae S, Mallick H, Franzosa EA, Lloyd-Price J, Bussell R, Thron T, Nelson AT, Wang M, Leszczynski E, Vargas F, Gauglitz JM, Meehan MJ, Gentry E, Arthur TD, Komor AC, Poulsen O, Boland BS, Chang JT, Sandborn WJ, Lim M, Garg N, Lumeng JC, Xavier RJ, Kazmierczak BI, Jain R, Egan M, Rhee KE, Ferguson D, Raffatellu M, Vlamakis H, Haddad GG, Siegel D, Huttenhower C, Mazmanian SK, Evans RM, Nizet V, Knight R, Dorrestein PC. Global chemical effects of the microbiome include new bile-acid conjugations. Nature 2020, 579: 123-129. PMID: 32103176, PMCID: PMC7252668, DOI: 10.1038/s41586-020-2047-9.Peer-Reviewed Original ResearchConceptsChemical interactionChemistryBile acid synthesis genesChemical effectsInflammatory bowel diseaseBile acid conjugatesCompoundsHost bile acidsMolecular familiesBile acid conjugationBowel diseaseGut diseasesMicrobiome dysbiosisConjugationAcidFree miceAmino acid conjugationBile acidsCystic fibrosisX receptorAcid conjugationReduced expressionFurther studiesDiseaseMiceImplications of the Gut Microbiome in Parkinson's Disease
Elfil M, Kamel S, Kandil M, Koo BB, Schaefer SM. Implications of the Gut Microbiome in Parkinson's Disease. Movement Disorders 2020, 35: 921-933. PMID: 32092186, DOI: 10.1002/mds.28004.Peer-Reviewed Original ResearchConceptsParkinson's disease patientsDisease patientsParkinson's diseaseMotor symptomsNervous systemEnteric nervous systemGut microbiome dysbiosisGut microbiome changesDifferent body systemsRelease of neurotoxinsCentral nervous systemCommon neurodegenerative disorderNormal gut microbiomeΑ-synuclein aggregatesNonmotor manifestationsAutoimmune responseNeuroprotective factorsAutopsy studyDopaminergic neuronsSubstantia nigraPathophysiologic changesMicrobiome dysbiosisMotor featuresGastrointestinal systemSystemic circulation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply